VMC
59
3
IFF
60
-6
C
79
5
WM
56
3
BA
43
-2
INTU
53
2
YUM
52
2
MCHP
55
6
HUM
36
7
HD
35
3
MA
48
2
KSS
58
-2
V
42
-2
ETN
63
3
AAP
42
3
AMP
67
3
UAL
87
5
THC
60
-4
COP
47
2
PBI
45
6
VMC
59
3
IFF
60
-6
C
79
5
WM
56
3
BA
43
-2
INTU
53
2
YUM
52
2
MCHP
55
6
HUM
36
7
HD
35
3
MA
48
2
KSS
58
-2
V
42
-2
ETN
63
3
AAP
42
3
AMP
67
3
UAL
87
5
THC
60
-4
COP
47
2
PBI
45
6
Financhill
Back

Protalix Biotherapeutics, Inc. 10K Form

Sell
40

PLX
Protalix Biotherapeutics, Inc.

Last Price:
$1.75
Seasonality Move:
85.19%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive PLX News And Ratings

See the #1 stock for the next 7 days that we like better than PLX

PLX Financial Statistics

Sales & Book Value

Annual Sales: $53.4M
Cash Flow: $-4.2M
Price / Cash Flow: 19.31
Annual Sales: $0.66
Price / Book: 2.61

Profitability

EPS (TTM): 0.06950
Net Income (TTM): $5.4M
Gross Margin: $29.1M
Return on Equity: 12.06%
Return on Assets: 7.3%

Protalix Biotherapeutics, Inc. Earnings Forecast

Key Protalix Biotherapeutics, Inc. Financial Ratios

  • The Gross Profit Margin over the past 27 years for PLX is 54.46%.
  • The Selling, General & Administrative Expenses for PLX have been equal to 22.83% of Gross Profit Margin.
  • The Research & Development expenses have been 24.29% of Revenue.
  • The Interest Expense is 36.22% of Operating Income.
  • The Net Earning history of PLX is 5.49% of Total Revenues.
  • Per Share Earnings over the last 29 years have been positive in 13 years.

Protalix Biotherapeutics, Inc. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NYAM
Industry: Biotechnology
Sector: Health Care
Current Symbol: PLX
CUSIP: 74365A
Website: protalix.com

Debt

Debt-to-Equity Ratio: 0.15
Current Ratio: 3.03
Quick Ratio: 2

Price-to-Earnings

Trailing P/E Ratio: 46.99
Forward P/E Ratio: 0

PLX Technical Analysis vs Fundamental Analysis

Sell
40
Protalix Biotherapeutics, Inc. (PLX) is a Sell

Is Protalix Biotherapeutics, Inc. a Buy or a Sell?